N@N

NUVASIVE INC (NASDAQ:NUVA), Down By 7.06% ($1.14) From $16.140 After BUYINS.NET Report Predicted Weakness After Earnings

^{Published on 2012-02-23 07:40:57 - WOPRAI}
 

February 23, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, February 21st 2012 stating that NUVASIVE INC (NASDAQ:NUVA) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=nuva&id=244982

At the time this story was written, NUVASIVE INC (NASDAQ:NUVA) is Down By 7.06% ($1.14) From $16.140 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

NUVASIVE INC (NASDAQ:NUVA) - NuVasive, Inc., a medical device company, engages in the design, development, and marketing of products for the surgical treatment of spine disorders. Its products are used in applications for spine fusion surgery. The companys products include a minimally disruptive surgical platform called Maximum Access Surgery (MAS), as well as cervical, biologics, and motion preservation products. Its MAS platform combines four categories of product offerings, including NeuroVision, a proprietary software-driven nerve avoidance system; MaXcess, a split-blade design retraction system providing enhanced surgical access to the spine; Biologics, which includes FormaGraft and Osteocel line of products; and specialized implants, such as SpheRx and Armadatm pedicle screw systems, CoRoent suite of implants, and various fixation systems. The company also offers a range of bone allograft in patented saline packaging and spine implants, such as rods, plates, and screws, as well as Osteocel, a bone matrix product that offers three properties related to autograft, including osteoconduction, osteoinduction, and osteogenesis. In addition, it is developing motion preservation products, including lateral total disc replacement device. The company sells its products through independent sales agencies and direct sales representatives primarily in the United States. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. NUVASIVE INC (NASDAQ:NUVA) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net